

Jan Cornel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2876832/publications.pdf>

Version: 2024-02-01

267
papers

44,501
citations

10986

71
h-index

1980

206
g-index

284
all docs

284
docs citations

284
times ranked

31796
citing authors

#	ARTICLE	IF	CITATIONS
1	The challenge of choosing in cardiovascular risk management. Netherlands Heart Journal, 2022, 30, 47-57.	0.8	5
2	Targeting residual inflammatory risk in coronary disease: to catch a monkey by its tail. Netherlands Heart Journal, 2022, 30, 25-37.	0.8	3
3	Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease. American Journal of Medicine, 2022, 135, 32-38.	1.5	41
4	Emphasis on prevention: how to approach residual cardiovascular risk. Netherlands Heart Journal, 2022, 30, 1-2.	0.8	0
5	Long-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease: Insights From LoDoCo2. Circulation, 2022, 145, 626-628.	1.6	9
6	Colchicine for secondary prevention in coronary disease. European Heart Journal, 2021, 42, 1060-1061.	2.2	4
7	Characteristics and prognostic value of right ventricular (dys)function in patients with non-ischaemic dilated cardiomyopathy assessed with cardiac magnetic resonance imaging. ESC Heart Failure, 2021, 8, 1055-1063.	3.1	12
8	Letter to the editor: Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e71-e71.	3.0	1
9	Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. European Heart Journal, 2021, 42, 2765-2775.	2.2	119
10	Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTEMI-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. European Heart Journal, 2021, 42, 2973-2985.	2.2	21
11	Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome. Journal of the American College of Cardiology, 2021, 78, 859-866.	2.8	27
12	Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: A LoDoCo2 biomarker substudy. Atherosclerosis, 2021, 334, 93-100.	0.8	25
13	Temporal changes of biomarkers in myocardial infarction patients with non-obstructive compared to obstructive coronary arteries. European Heart Journal, 2021, 42, .	2.2	0
14	IGF-1 is not related to long-term outcome in hyperglycemic acute coronary syndrome patients. Diabetes and Vascular Disease Research, 2021, 18, 147916412110474.	2.0	1
15	Allopurinol to reduce cardiovascular morbidity and mortality: A systematic review and meta-analysis. PLoS ONE, 2021, 16, e0260844.	2.5	11
16	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. Journal of the American College of Cardiology, 2020, 75, 133-144.	2.8	296
17	ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. Atherosclerosis, 2020, 293, 35-41.	0.8	5
18	Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease. Circulation, 2020, 142, 1996-1998.	1.6	81

#	ARTICLE	IF	CITATIONS
19	Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C-reactive protein. PLoS ONE, 2020, 15, e0237665.	2.5	29
20	Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine, 2020, 383, 1838-1847.	27.0	1,010
21	Correlation between septal midwall late gadolinium enhancement on CMR and conduction delay on ECG in patients with nonischemic dilated cardiomyopathy. IJC Heart and Vasculature, 2020, 26, 100474.	1.1	4
22	Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PREvention of Acute rEspiraTORY dIstress syndrome in hospItAlized patieNts with SARS-COV-2 Infection Disease. American Heart Journal, 2020, 226, 60-68.	2.7	12
23	Electronic health records to facilitate continuous detection of familial hypercholesterolemia. Atherosclerosis, 2020, 310, 83-87.	0.8	9
24	Relation between pharmacological stress ECG, 13NH3-PET/CT outcome and the occurrence of cardiac events during follow-up in women with chest pain. Nuclear Medicine Communications, 2020, 41, 783-789.	1.1	0
25	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome. Journal of the American College of Cardiology, 2019, 74, 1167-1176.	2.8	154
26	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology, 2019, 7, 618-628.	11.4	207
27	Repeated Echocardiograms Do Not Provide Incremental Prognostic Value to Single Echocardiographic Assessment in Minimally Symptomatic Patients with Chronic Heart Failure: Results of the Bio-SHiFT Study. Journal of the American Society of Echocardiography, 2019, 32, 1000-1009.	2.8	7
28	The effect of low-dose colchicine in patients with stable coronary artery disease: The LoDoCo2 trial rationale, design, and baseline characteristics. American Heart Journal, 2019, 218, 46-56.	2.7	72
29	Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies Attenuate Arterial Wall Inflammation In Statin Intolerant Patients In Absence Of Crp Change. Atherosclerosis, 2019, 287, e12.	0.8	0
30	PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers. JACC: Cardiovascular Imaging, 2019, 12, 2571-2573.	5.3	44
31	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005858.	2.2	17
32	Longitudinally Measured Fibrinolysis Factors are Strong Predictors of Clinical Outcome in Patients with Chronic Heart Failure: The Bio-SHiFT Study. Thrombosis and Haemostasis, 2019, 119, 1947-1955.	3.4	14
33	Associations between β -blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease. American Heart Journal, 2019, 218, 92-99.	2.7	4
34	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet, 2019, 394, 1169-1180.	13.7	155
35	Ticagrelor in Patients with Stable Coronary Disease and Diabetes. New England Journal of Medicine, 2019, 381, 1309-1320.	27.0	255
36	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. Journal of the American College of Cardiology, 2019, 74, 1177-1186.	2.8	49

#	ARTICLE	IF	CITATIONS
37	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 1578-1589.	1.6	34
38	International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. <i>American Heart Journal</i> , 2019, 218, 57-65.	2.7	4
39	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2019, 40, 2801-2809.	2.2	45
40	P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019, 4, 680.	6.1	9
41	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 103-112.	1.6	107
42	ASSOCIATIONS BETWEEN BETA-BLOCKER THERAPY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIABETES AND ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM THE TECOS STUDY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 138.	2.8	1
43	Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y ₁₂ Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e011139.	3.7	33
44	Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. <i>Clinical Cardiology</i> , 2019, 42, 498-505.	1.8	24
45	Colchicine in Stable Coronary Artery Disease. <i>Clinical Therapeutics</i> , 2019, 41, 30-40.	2.5	23
46	Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. <i>Circulation</i> , 2019, 139, 1289-1299.	1.6	384
47	P595 Characteristics of the right ventricle in patients with nonischemic dilated cardiomyopathy. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
48	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 489-496.	2.8	56
49	Toward personalized risk assessment in patients with chronic heart failure: Detailed temporal patterns of NT-proBNP, troponin T, and CRP in the Bio-SHIFT study. <i>American Heart Journal</i> , 2018, 196, 36-48.	2.7	40
50	Exercise Electrocardiogram Neither Predicts Nor Excludes Coronary Artery Disease in Women with Low to Intermediate Risk. <i>Journal of Women's Health</i> , 2018, 27, 476-484.	3.3	2
51	The Prognostic Value of Late Gadolinium-Enhanced Cardiac Magnetic Resonance Imaging in Nonischemic Dilated Cardiomyopathy. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1274-1284.	5.3	196
52	Patient-specific evolution of renal function in chronic heart failure patients dynamically predicts clinical outcome in the Bio-SHIFT study. <i>Kidney International</i> , 2018, 93, 952-960.	5.2	26
53	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. <i>Lancet</i> , The, 2018, 391, 319-328.	13.7	628
54	P4687 Midwall late gadolinium enhancement in both nonischemic cardiomyopathy and ischemic heart disease. <i>European Heart Journal</i> , 2018, 39, .	2.2	0

#	ARTICLE	IF	CITATIONS
55	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 2018, 379, 2097-2107.	27.0	2,211
56	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, The, 2018, 392, 1519-1529.	13.7	1,179
57	Inhibition of Interleukin-1 β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. Journal of the American College of Cardiology, 2018, 71, 2405-2414.	2.8	186
58	Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. American Heart Journal, 2017, 186, 91-99.	2.7	36
59	Serially measured circulating miR-22-3p is a biomarker for adverse clinical outcome in patients with chronic heart failure: The Bio-SHiFT study. International Journal of Cardiology, 2017, 235, 124-132.	1.7	36
60	Early Invasive Versus Selective Strategy for Non-ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology, 2017, 69, 1883-1893.	2.8	29
61	Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS. Diabetes, Obesity and Metabolism, 2017, 19, 1587-1593.	4.4	24
62	Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus. Circulation, 2017, 136, 1193-1203.	1.6	47
63	Temporal Biomarker Profiling Reveals Longitudinal Changes in Risk of Death or Myocardial Infarction in Non-ST-Segment Elevation Acute Coronary Syndrome. Clinical Chemistry, 2017, 63, 1214-1226.	3.2	9
64	Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes. Heart, 2017, 103, 1168-1176.	2.9	34
65	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine, 2017, 376, 1713-1722.	27.0	4,179
66	Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y ₁₂ inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet, The, 2017, 389, 1799-1808.	13.7	174
67	Effect of interleukin-1 β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 1833-1842.	13.7	948
68	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine, 2017, 377, 1119-1131.	27.0	6,227
69	In search of an efficient strategy to monitor disease status of chronic heart failure outpatients: added value of blood biomarkers to clinical assessment. Netherlands Heart Journal, 2017, 25, 634-642.	0.8	6
70	Discriminative Power of the HEART Score for Obstructive Coronary Artery Disease in Acute Chest Pain Patients Referred for CCTA. Critical Pathways in Cardiology, 2016, 15, 6-10.	0.5	3
71	Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus. JAMA Cardiology, 2016, 1, 126.	6.1	196
72	Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2016, 67, 2135-2144.	2.8	66

#	ARTICLE	IF	CITATIONS
91	Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2014, 112, 883-891.	3.4	27
92	Dehiscence of mitral valve annuloplasty: a three-dimensional diagnosis. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 45, 393-393.	1.4	0
93	Coronary artery disease in patients with atypical chest pain with and without diabetes mellitus assessed with coronary CT angiography. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000004.	2.8	15
94	Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial. <i>American Heart Journal</i> , 2014, 168, 869-877.e1.	2.7	21
95	Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization. <i>Circulation</i> , 2014, 129, 293-303.	1.6	100
96	Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. <i>American Heart Journal</i> , 2014, 168, 76-87.e1.	2.7	22
97	Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2014, 168, 68-75.e2.	2.7	18
98	Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. <i>European Heart Journal</i> , 2014, 35, 2083-2093.	2.2	171
99	Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study. <i>EuroIntervention</i> , 2014, 10, 431-438.	3.2	26
100	Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: Insights from the PLATElet inhibition and patient outcomes (PLATO) trial. <i>American Heart Journal</i> , 2013, 166, 474-480.	2.7	28
101	Coronary Artery Pseudoaneurysm: Closure With Pericardium-Covered Stents, Guided by Cardiac Computed Tomography Angiography. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1014.e11-1014.e12.	1.7	2
102	Intensive glucose regulation does not reduce enzymatic infarct size in hyperglycemic acute coronary syndromes: results of the randomized BIOMArCS-2 glucose trial. <i>European Heart Journal</i> , 2013, 34, P467-P467.	2.2	0
103	A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. <i>European Heart Journal</i> , 2013, 34, 2481-2489.	2.2	85
104	Intensive Glucose Regulation in Hyperglycemic Acute Coronary Syndrome. <i>JAMA Internal Medicine</i> , 2013, 173, 1896.	5.1	43
105	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. <i>New England Journal of Medicine</i> , 2012, 367, 1297-1309.	27.0	765
106	Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1785.	7.4	200
107	Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2012, 366, 20-33.	27.0	701
108	Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes—Insights from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>American Heart Journal</i> , 2012, 164, 334-342.e1.	2.7	53

#	ARTICLE	IF	CITATIONS
109	Translational platelet research in patients with coronary artery disease: What are the major knowledge gaps?. Thrombosis and Haemostasis, 2012, 108, 12-20.	3.4	9
110	nâ€“3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. New England Journal of Medicine, 2012, 367, 309-318.	27.0	810
111	Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine, 2012, 367, 319-328.	27.0	1,426
112	TCT-176: Access and non-Access Site Bleeding in Acute Coronary Syndrome Patients Treated with a Novel Actively Reversible Factor IXa Inhibitor. Results from the RADAR Trial. Journal of the American College of Cardiology, 2011, 58, B47.	2.8	0
113	Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. New England Journal of Medicine, 2011, 365, 699-708.	27.0	918
114	Reply to Huang. American Heart Journal, 2011, 161, e3.	2.7	5
115	A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial. American Heart Journal, 2011, 161, 261-268.e2.	2.7	36
116	N-Terminal Pro B-Type Natriuretic Peptide Identifies Patients with Chest Pain at High Long-term Cardiovascular Risk. American Journal of Medicine, 2011, 124, 961-969.	1.5	9
117	Intensive management of hyperglycaemia in acute coronary syndromes. Study design and rationale of the BIOMArCSâ€“f2 glucose trial. Diabetic Medicine, 2011, 28, 1168-1175.	2.3	7
118	Long-term Clinical Outcome and MIBI SPECT Parameters in Percutaneous Coronary Interventions. Netherlands Heart Journal, 2011, 19, 68-72.	0.8	2
119	GRACE and TIMI risk scores but not stress imaging predict long-term cardiovascular follow-up in patients with chest pain after a rule-out protocol. Netherlands Heart Journal, 2011, 19, 324-330.	0.8	8
120	Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ: British Medical Journal, 2011, 342, d3527-d3527.	2.3	246
121	Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal, 2011, 32, 2933-2944.	2.2	335
122	The direct inverse method: A novel approach to estimate adsorption isotherm parameters. Journal of Chromatography A, 2010, 1217, 1934-1941.	3.7	17
123	Experimental evidence of a delta-shock in nonlinear chromatography. Journal of Chromatography A, 2010, 1217, 2002-2012.	3.7	48
124	Lenient versus Strict Rate Control in Patients with Atrial Fibrillation. New England Journal of Medicine, 2010, 362, 1363-1373.	27.0	851
125	Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal, 2010, 31, 3006-3016.	2.2	389
126	Elevated admission glucose is associated with increased long-term mortality in myocardial infarction patients, irrespective of the initially applied reperfusion strategy. American Heart Journal, 2010, 160, 412-419.	2.7	38

#	ARTICLE	IF	CITATIONS
127	Precipitation and Transformation of the Three Polymorphs of α -Mannitol. Industrial & Engineering Chemistry Research, 2010, 49, 5854-5862.	3.7	56
128	Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function. Circulation, 2010, 122, 1056-1067.	1.6	354
129	Cystatin C for Enhancement of Risk Stratification in Non-ST Elevation Acute Coronary Syndrome Patients with an Increased Troponin T. Clinical Chemistry, 2009, 55, 1118-1125.	3.2	38
130	Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-II, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. European Journal of Heart Failure, 2009, 11, 281-291.	7.1	120
131	Infarct size in primary angioplasty without on-site cardiac surgical backup versus transferal to a tertiary center: a single photon emission computed tomography study. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 237-243.	6.4	1
132	Monitoring size and shape during cooling crystallization of ascorbic acid. Chemical Engineering Science, 2009, 64, 163-171.	3.8	16
133	One-year mortality after a first visit to a cardiology outpatient clinic: a useful performance indicator?. Netherlands Heart Journal, 2009, 17, 52-55.	0.8	2
134	Estimating Crystal Growth Rates Using in situ ATR-FTIR and Raman Spectroscopy in a Calibration-Free Manner. Industrial & Engineering Chemistry Research, 2009, 48, 10740-10745.	3.7	26
135	The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRAACER) trial: study design and rationale. American Heart Journal, 2009, 158, 327-334.e4.	2.7	120
136	Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin. Journal of the American College of Cardiology, 2009, 54, 1850-1859.	2.8	200
137	Experimental Characterization and Population Balance Modeling of the Polymorph Transformation of α -Glutamic Acid. Crystal Growth and Design, 2009, 9, 243-252.	3.0	79
138	Design and Optimization of a Combined Cooling/Antisolvent Crystallization Process. Crystal Growth and Design, 2009, 9, 1124-1136.	3.0	154
139	Dutch Randomized Trial on Off-Site Primary PCI. American Journal of Cardiology, 2008, 102, 1115.	1.6	0
140	Quantitative Application of in Situ ATR-FTIR and Raman Spectroscopy in Crystallization Processes. Industrial & Engineering Chemistry Research, 2008, 47, 4870-4882.	3.7	121
141	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2008, 372, 807-816.	13.7	934
142	Calibration-Free Quantitative Application of in Situ Raman Spectroscopy to a Crystallization Process. Analytical Chemistry, 2008, 80, 9240-9249.	6.5	19
143	Diverging associations of an intended early invasive strategy compared with actual revascularization, and outcome in patients with non-ST-segment elevation acute coronary syndrome: the problem of treatment selection bias. European Heart Journal, 2008, 30, 645-654.	2.2	33
144	The BEAUTIFUL Study: Randomized Trial of Ivabradine in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction – Baseline Characteristics of the Study Population. Cardiology, 2008, 110, 271-282.	1.4	39

#	ARTICLE	IF	CITATIONS
145	Rosuvastatin in Older Patients with Systolic Heart Failure. New England Journal of Medicine, 2007, 357, 2248-2261.	27.0	1,330
146	Inhibition of nonlinear acoustic cavitation dynamics in liquid CO ₂ . Journal of Chemical Physics, 2007, 126, 064508.	3.0	12
147	Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer Alkmaar heart failure study. Heart, 2007, 93, 819-825.	2.9	114
148	N-terminal pro-BNP brain natriuretic peptide for additional risk stratification in patients with non-ST-elevation acute coronary syndrome and an elevated troponin T: An Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. American Heart Journal, 2007, 153, 485-492.	2.7	41
149	The impact of admission plasma glucose on long-term mortality after STEMI and NSTEMI myocardial infarction. International Journal of Cardiology, 2007, 121, 215-217.	1.7	18
150	Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. Lancet, The, 2007, 369, 827-835.	13.7	132
151	Percutaneous Coronary Intervention With Off-Site Cardiac Surgery Backup for Acute Myocardial Infarction as a Strategy to Reduce Door-to-Balloon Time. American Journal of Cardiology, 2007, 100, 1353-1358.	1.6	31
152	ST-segment deviation on the admission electrocardiogram, treatment strategy, and outcome in non-ST-elevation acute coronary syndromes. Journal of Electrocardiology, 2007, 40, 408-415.	0.9	14
153	Diagnostiek bij hartfalen. , 2007, , 71-93.		0
154	Rate Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. American Heart Journal, 2006, 152, 420-426.	2.7	76
155	Safety and efficacy of a nurse-led clinic for post-operative coronary artery bypass grafting patients. International Journal of Cardiology, 2006, 106, 111-115.	1.7	20
156	Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure. Circulation, 2006, 113, 671-678.	1.6	817
157	Patient work in end-stage heart failure: a prospective longitudinal multiple case study. Palliative Medicine, 2006, 20, 25-33.	3.1	22
158	Myocardial β -adrenoceptor downregulation in idiopathic dilated cardiomyopathy measured in vivo with PET using the new radioligand (S)-[¹¹ C]CGP12388. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 443-447.	6.4	52
159	The value of haemostatic markers in the triage of patients with chest pain presenting with a normal or non-diagnostic ECG. Heart, 2005, 91, 1215-1216.	2.9	1
160	Heart failure programmes in countries with a primary care-based health care system. Are additional trials necessary? Design of the DEAL-HF study. European Journal of Heart Failure, 2005, 7, 910-920.	7.1	24
161	Early Invasive versus Selectively Invasive Management for Acute Coronary Syndromes. New England Journal of Medicine, 2005, 353, 1095-1104.	27.0	485
162	A man with diabetes and heart failure. Lancet, The, 2004, 364, 636.	13.7	4

#	ARTICLE	IF	CITATIONS
163	Heart failure: chapter 4. Evaluation of patients with suspected heart failure. Netherlands Heart Journal, 2004, 12, 412-416.	0.8	0
164	Endothelial dysfunction and reduced myocardial perfusion reserve in heart failure secondary to coronary artery disease. American Journal of Cardiology, 2003, 91, 497-500.	1.6	10
165	Prognostic value of predischage dobutamine stress echocardiography in chest pain patients with a negative cardiac troponin T. Journal of the American College of Cardiology, 2003, 41, 596-602.	2.8	104
166	The prognostic value of markers of inflammation in patients with troponin Tâ€“negative chest pain before discharge from the emergency department. American Journal of Medicine, 2003, 115, 521-528.	1.5	20
167	Dobutamine stress echocardiography is a valuable diagnostic test for predischage risk assessment in low-risk chest pain patients. Evidence-based Cardiovascular Medicine, 2003, 7, 203-205.	0.0	0
168	Relaxivity Studies on Dinitroxide and Polynitroxyl Functionalized Dendrimers:Â Effect of Electron Exchange and Structure on Paramagnetic Relaxation Enhancement. Journal of Physical Chemistry A, 2003, 107, 8467-8475.	2.5	46
169	P2315 The added value of pre-discharge dobutamine stress echocardiography in the long-term risk stratification of chest pain patients. European Heart Journal, 2003, 24, 447.	2.2	0
170	P400 Myocardial beta-adrenoceptor downregulation in idiopathic dilated cardiomyopathy measured in vivo using (S)-611C9CGP 12388 and positron emission tomography. European Heart Journal, 2003, 24, 51.	2.2	0
171	Sequential (201)Tl imaging and dobutamine echocardiography to enhance accuracy of predicting improved left ventricular ejection fraction after revascularization. Journal of Nuclear Medicine, 2002, 43, 795-802.	5.0	25
172	Impaired glucose metabolism predicts mortality after a myocardial infarction. International Journal of Cardiology, 2001, 79, 207-214.	1.7	195
173	Abnormal contractile responses during dobutamine stress echocardiography in patients with idiopathic dilated cardiomyopathy. European Journal of Heart Failure, 2001, 3, 429-436.	7.1	18
174	Possible Bradycardic Mode of Death and Successful Pacemaker Treatment in a Large Family with Features of Long QT Syndrome Type 3 and Brugada Syndrome. Journal of Cardiovascular Electrophysiology, 2001, 12, 630-636.	1.7	140
175	Time Course of Functional Recovery of Stunned and Hibernating Segments After Surgical Revascularization. Circulation, 2001, 104, I-314-I-318.	1.6	180
176	Time Course of Functional Recovery of Stunned and Hibernating Segments After Surgical Revascularization. Circulation, 2001, 104, .	1.6	5
177	Relationship between preoperative viability and postoperative improvement in LVEF and heart failure symptoms. Journal of Nuclear Medicine, 2001, 42, 79-86.	5.0	55
178	Effect of coronary artery bypass surgery on myocardial perfusion and ejection fraction response to inotropic stimulation in patients without improvement in resting ejection fraction. American Journal of Cardiology, 2000, 86, 490-494.	1.6	6
179	Safety and prognostic value of early dobutamineâ€“atropine stress echocardiography in patients with spontaneous chest pain and a non-diagnostic electrocardiogram. European Heart Journal, 2000, 21, 397-406.	2.2	90
180	Usefulness and limitations of dobutamineâ€“atropine stress echocardiography for the diagnosis of coronary artery disease in patients with left bundle branch block. A multicentre study. European Heart Journal, 2000, 21, 1666-1673.	2.2	77

#	ARTICLE	IF	CITATIONS
181	Safety and efficacy of treatment with platelet GPIIb/IIIa receptor blockade in unstable angina patients awaiting PTCA at a referring clinic. International Journal of Cardiovascular Interventions, 1999, 2, 223-230.	0.5	0
182	Delayed recovery of hibernating myocardium after surgical revascularization: Implications for discrepancy between metabolic imaging and dobutamine echocardiography for assessment of myocardial viability. Journal of Nuclear Cardiology, 1999, 6, 685-687.	2.1	14
183	Agreement and disagreement between $\text{^{18}F}$ -metabolic viability and $\text{^{18}F}$ -contractile reserve in akinetic myocardium. Journal of Nuclear Cardiology, 1999, 6, 383-388.	2.1	35
184	Dobutamine stress thallium-201 single-photon emission tomography versus echocardiography for evaluation of the extent and location of coronary artery disease late after myocardial infarction. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 467-473.	6.4	4
185	Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet, The, 1999, 353, 2001-2007.	13.7	4,616
186	Echocardiographic Studies of Dobutamine-Induced ST-Segment Elevation Before and After Coronary Artery Bypass Grafting in Patients with Old Q-Wave Myocardial Infarction. Journal of the American Society of Echocardiography, 1999, 12, 48-54.	2.8	5
187	Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography. Journal of the American College of Cardiology, 1999, 34, 163-169.	2.8	318
188	Relation between Viability, Improvement of Lvef and Heart Failure Symptoms after Revascularization. , 1999, , 223-227.		0
189	Prediction of improvement of regional left ventricular function after revascularization using different perfusion-metabolism criteria. Journal of Nuclear Medicine, 1999, 40, 1866-73.	5.0	17
190	Dobutamine-atropine stress myocardial perfusion SPECT imaging in the diagnosis of graft stenosis after coronary artery bypass grafting*1. Journal of Nuclear Cardiology, 1998, 5, 491-497.	2.1	23
191	Biphasic Response to Dobutamine Predicts Improvement of Global Left Ventricular Function After Surgical Revascularization in Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology, 1998, 31, 1002-1010.	2.8	159
192	Prognostic Implications of a Normal Dobutamine-Atropine Stress Echocardiogram in Patients with Chest Pain. Journal of the American Society of Echocardiography, 1998, 11, 606-611.	2.8	8
193	Safety and utility of atropine addition during dobutamine stress echocardiography for the assessment of viable myocardium in patients with severe left ventricular dysfunction. European Heart Journal, 1998, 19, 1712-1718.	2.2	43
194	FDG SPECT to Assess Myocardial Viability. Developments in Cardiovascular Medicine, 1998, , 249-260.	0.1	0
195	Assessment of myocardial viability by FDG imaging with SPECT. Developments in Cardiovascular Medicine, 1998, , 299-309.	0.1	0
196	Identification of Patients With Improvement of LVEF and Heart Failure Symptoms by Combined Low-High Dose Dobutamine Echocardiography. Journal of the American College of Cardiology, 1998, 31, 82A.	2.8	2
197	Prediction of Improvement of Left Ventricular Function and Heart Failure Symptoms by FDG SPECT. Journal of the American College of Cardiology, 1998, 31, 300A.	2.8	2
198	Comparison of fluorine-18-FDG with rest-redistribution thallium-201 SPECT to delineate viable myocardium and predict functional recovery after revascularization. Journal of Nuclear Medicine, 1998, 39, 1481-6.	5.0	24

#	ARTICLE	IF	CITATIONS
199	Digoxin in Patients with Heart Failure. New England Journal of Medicine, 1997, 337, 129-131.	27.0	7
200	Relation between ST segment elevation during dobutamine stress test and myocardial viability after a recent myocardial infarction.. Heart, 1997, 77, 115-121.	2.9	22
201	FDG SPECT in the assessment of myocardial viability: Comparison with dobutamine echo. European Heart Journal, 1997, 18, 124-129.	2.2	9
202	Prediction of improvement of ventricular function after revascularization: 18F-fluorodeoxyglucose single-photon emission computed tomography vs low-dose dobutamine echocardiography. European Heart Journal, 1997, 18, 941-948.	2.2	19
203	Cardiac 18F-FDG-SPET studies in patients with non-insulin-dependent diabetes mellitus during hyperinsulinaemic euglycaemic clamping. Nuclear Medicine Communications, 1997, 18, 200-206.	1.1	11
204	Comparison between 360° and 180° data sampling in thallium-201 rest-redistribution single-photon emission tomography to predict functional recovery after revascularization. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 516-522.	2.1	12
205	Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; a comparative study using different protocols. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 35-41.	2.1	72
206	Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet, The, 1997, 349, 1429-1435.	13.7	1,241
207	Prediction of Improvement of Contractile Function in Patients With Ischemic Ventricular Dysfunction After Revascularization by Fluorine-18 Fluorodeoxyglucose Single-Photon Emission Computed Tomography. Journal of the American College of Cardiology, 1997, 30, 377-383.	2.8	79
208	Accuracy of Currently Available Techniques for Prediction of Functional Recovery After Revascularization in Patients With Left Ventricular Dysfunction Due to Chronic Coronary Artery Disease: Comparison of Pooled Data. Journal of the American College of Cardiology, 1997, 30, 1451-1460.	2.8	488
209	Impact of Severity of Coronary Artery Stenosis and the Collateral Circulation on the Functional Outcome of Dyssynergic Myocardium After Revascularization in Patients With Healed Myocardial Infarction and Chronic Left Ventricular Dysfunction. American Journal of Cardiology, 1997, 79, 883-888.	1.6	30
210	Predictive Accuracy of Echocardiographic Response of Mildly Dyssynergic Myocardial Segments to Low-Dose Dobutamine. American Journal of Cardiology, 1997, 80, 1481-1484.	1.6	12
211	Dobutamine stress-redistribution-reinjection versus rest-redistribution thallium-201 SPECT in the assessment of myocardial viability. International Journal of Cardiovascular Imaging, 1997, 13, 59-64.	0.6	3
212	Metabolic imaging using F18-fluorodeoxyglucose to assess myocardial viability. International Journal of Cardiovascular Imaging, 1997, 13, 145-155.	0.6	29
213	Improved detection of viable myocardium with fluorodeoxyglucose-labeled single-photon emission computed tomography in a patient with hibernating myocardium: Comparison with rest-redistribution thallium 201-labeled single-photon emission computed tomography. Journal of Nuclear Cardiology, 1997, 4, 178-179.	2.1	6
214	F18-fluorodeoxyglucose single-photon emission computed tomography predicts functional outcome of dyssynergic myocardium after surgical revascularization. Journal of Nuclear Cardiology, 1997, 4, 302-308.	2.1	24
215	Hemodynamic Changes, Plasma Catecholamine Responses, and Echocardiographically Detected Contractile Reserve During Two Different Dobutamine-Infusion Protocols. Journal of Cardiovascular Pharmacology, 1997, 29, 808-813.	1.9	4
216	Cardiac Imaging for Risk Stratification With Dobutamine-Atropine Stress Testing in Patients With Chest Pain. Circulation, 1997, 96, 137-147.	1.6	92

#	ARTICLE	IF	CITATIONS
217	Prediction of Improvement in Global and Regional Ventricular Function after Revascularization with FDG SPECT. , 1997, , 173-178.		0
218	Detection of myocardial viability with F-18-fluorodeoxyglucose and single photon emission computed tomography. Giornale Italiano Di Cardiologia, 1997, 27, 1181-6.	0.2	2
219	Safety and feasibility of dobutamine-atrophine stress echocardiography in patients with ischemic left ventricular dysfunction1. Journal of the American Society of Echocardiography, 1996, 9, 27-32.	2.8	37
220	Comparison of thallium-201 rest-redistribution SPECT and FDG SPECT in predicting functional recovery after revascularization. Journal of the American College of Cardiology, 1996, 27, 300-301.	2.8	2
221	Dobutamine-induced hypoperfusion without transient wall motion abnormalities: Less severe ischemia or less severe stress?. Journal of the American College of Cardiology, 1996, 27, 323-329.	2.8	54
222	Prognostic value of dobutamine-atropine stress technetium-99m sestamibi perfusion scintigraphy in patients with chest pain. Journal of the American College of Cardiology, 1996, 28, 447-454.	2.8	48
223	Prediction of recovery of myocardial dysfunction after revascularization comparison of fluorine-18 fluorodeoxyglucose/thallium-201 SPECT, thallium-201 stress-reinjection SPECT and dobutamine echocardiography. Journal of the American College of Cardiology, 1996, 28, 558-564.	2.8	198
224	Low-dose dobutamine echocardiography and rest-redistribution thallium-201 tomography in the assessment of spontaneous recovery of left ventricular function after recent myocardial infarction. American Heart Journal, 1996, 131, 1088-1096.	2.7	35
225	Altered myocardial perfusion during dobutamine stress testing in silent versus symptomatic myocardial ischaemia assessed by quantitative MIBI SPET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 1354-1360.	2.1	8
226	Comprehensive analysis of aortic valve vegetation with anyplane, paraplane, and three-dimensional echocardiography. European Heart Journal, 1996, 17, 318-320.	2.2	9
227	Prediction of reversibility of wall motion abnormalities after revascularization using F18-fluorodeoxyglucose single photon emission computed tomography. European Heart Journal, 1996, 17, 480-481.	2.2	2
228	T wave normalization during dobutamine stress testing in patients with non-Q wave myocardial infarction. A marker of myocardial ischaemia?. European Heart Journal, 1996, 17, 526-531.	2.2	17
229	Akinesis Becoming Dyskinesia During Dobutamine Stress Echocardiography. Chest, 1996, 110, 155-158.	0.8	24
230	Relation between contractile response of akinetic segments during dobutamine stress echocardiography and myocardial ischemia assessed by simultaneous thallium-201 single-photon emission computed tomography. American Journal of Cardiology, 1996, 77, 955-959.	1.6	52
231	Prognostic significance of normal dobutamine-atropine stress sestamibi scintigraphy in women with chest pain. American Journal of Cardiology, 1996, 77, 1057-1061.	1.6	39
232	Assessment of patients after coronary artery bypass grafting by dobutamine stress echocardiography. American Journal of Cardiology, 1996, 77, 1234-1236.	1.6	19
233	Accuracy of dobutamine stress echocardiography for the diagnosis of coronary artery stenosis in patients with myocardial infarction: the impact of extent and severity of left ventricular dysfunction.. Heart, 1996, 76, 123-128.	2.9	27
234	Assessment of myocardial viability by dobutamine stress echocardiography. Current Opinion in Cardiology, 1996, 11, 621-626.	1.8	19

#	ARTICLE	IF	CITATIONS
235	Coronary-Artery Bypass Surgery with Internal-Thoracic-Artery Grafts. New England Journal of Medicine, 1996, 334, 1609-1610.	27.0	2
236	Prognostic Value of Dobutamine-Atropine Stress Technetium-99m Sestamibi Perfusion Scintigraphy in Patients With Chest Pain. Journal of the American College of Cardiology, 1996, 28, 447-454.	2.8	57
237	Prediction of Recovery of Myocardial Dysfunction After Revascularization Comparison of Fluorine-18 Fluorodeoxyglucose/Thallium-201 SPECT, Thallium-201 Stressâ€“Reinjection SPECT and Dobutamine Echocardiography. Journal of the American College of Cardiology, 1996, 28, 558-564.	2.8	16
238	Coronary-artery bypass surgery with internal-thoracic-artery grafts. New England Journal of Medicine, 1996, 334, 1609-10.	27.0	0
239	Dobutamine thallium-201 SPECT imaging for assessment of peri-infarction and remote myocardial ischemia. Journal of Nuclear Medicine, 1996, 37, 1951-6.	5.0	11
240	Improved identification of coronary artery disease in patients with left bundle branch block by use of dobutamine stress echocardiography and comparison with myocardial perfusion tomography. American Journal of Cardiology, 1995, 76, 321-325.	1.6	74
241	Evaluation by quantitative 99m-technetium MIBI SPECT and echocardiography of myocardial perfusion and wall motion abnormalities in patients with dobutamine-induced ST-segment elevation. American Journal of Cardiology, 1995, 76, 441-448.	1.6	50
242	T-Wave normalization during dobutamine echocardiography for diagnosis of viable myocardium. American Journal of Cardiology, 1995, 75, 505-507.	1.6	24
243	Stress-induced left ventricular dysfunction in silent and symptomatic myocardial ischemia during dobutamine stress test. American Journal of Cardiology, 1995, 75, 1112-1115.	1.6	12
244	Correlation of coronary stenosis by quantitative coronary arteriography with exercise echocardiography. American Journal of Cardiology, 1995, 75, 287-290.	1.6	16
245	Quantitative angiographic measurements of isolated left anterior descending coronary artery stenosis correlation with exercise echocardiography and technetium-99m 2-methoxy isobutyl isonitrile single-photon emission computed tomography. Journal of the American College of Cardiology, 1995, 25, 1486-1491.	2.8	24
246	937-4 Combined Use of Dobutamine Stress Echocardiography and Myocardial Contrast Echocardiography. Journal of the American College of Cardiology, 1995, 25, 159A-160A.	2.8	0
247	Prediction of Improvement of Regional Left Ventricular Function After Surgical Revascularization. Circulation, 1995, 91, 2748-2752.	1.6	250
248	Assessment of Myocardial Viability by Pharmacological Stress Echocardiography. Developments in Cardiovascular Medicine, 1995, , 103-115.	0.1	0
249	Dobutamine-Atropine Stress Echocardiography in Elderly Patients Unable to Perform an Exercise Test. Archives of Internal Medicine, 1994, 154, 2681.	3.8	45
250	Prediction of improvement of ventricular function after first acute myocardial infarction using low-dose dobutamine stress echocardiography. American Journal of Cardiology, 1994, 74, 853-856.	1.6	80
251	Safety of dobutamine-atropine stress echocardiography in patients with suspected or proven coronary artery disease. American Journal of Cardiology, 1994, 73, 456-459.	1.6	138
252	Akinesis becoming dyskinesia during high-dose dobutamine stress echocardiography: A marker of myocardial ischemia or a mechanical phenomenon?. American Journal of Cardiology, 1994, 73, 896-899.	1.6	135

#	ARTICLE	IF	CITATIONS
253	Dobutamine-atropine stress echocardiography and clinical data for predicting late cardiac events in patients with suspected coronary artery disease. American Journal of Medicine, 1994, 97, 119-125.	1.5	82
254	Potential and limitations of Tc-99m sestamibi scintigraphy for the diagnosis of myocardial viability. Herz, 1994, 19, 19-27.	1.1	8
255	Intracoronary albuterol. Its effects on left ventricular hemodynamics, function, and coronary sinus flow in humans.. Circulation, 1993, 88, 2123-2127.	1.6	39
256	Preliminary clinical experience with intracoronary Albuterol: a standardized echocontrast agent. Developments in Cardiovascular Medicine, 1993, , 109-120.	0.1	0
257	Exercise echocardiography versus thallium-201 SPECT for assessing patients before and after PTCA. European Heart Journal, 1992, 13, 213-219.	2.2	50
258	Myocardial contrast echocardiography can depict thebesian vein outflow in humans. American Heart Journal, 1992, 123, 1373-1374.	2.7	4
259	Relationship between exercise echocardiography and perfusion single-photon emission computed tomography in patients with single-vessel coronary artery disease. American Heart Journal, 1992, 124, 75-83.	2.7	57
260	Clinical experience with Albuterol: a standard echocontrast agent for intravenous and intracoronary use. American Journal of Cardiac Imaging, 1991, 5, 217-23.	0.2	5
261	Myocardial contrast echocardiography during hyperemia. Coronary Artery Disease, 1990, 1, 573-578.	0.7	3
262	The Effect of Multiple-Dose Oral Lomefloxacin on Theophylline Metabolism in Man. Chest, 1990, 98, 1440-1444.	0.8	18
263	Evaluation of collateral blood flow by myocardial contrast enhanced echocardiography.. Heart, 1988, 59, 20-22.	2.9	27
264	Detection of left coronary artery stenosis by transoesophageal echocardiography. European Heart Journal, 1988, 9, 1162-1166.	2.2	43
265	Effect of papaverine administration on myocardial echocontrast distribution. American Heart Journal, 1987, 114, 1248-1249.	2.7	10
266	Quantitative assessment of myocardial blood flow by contrast two-dimensional echocardiography: initial clinical observations. American Journal of Physiologic Imaging, 1987, 2, 56-60.	0.1	8
267	Synthetic Peer Benchmarking for Diversified Private Equity Programs. Journal of Alternative Investments, 0, , .	0.5	1